Naltrexone versus buprenorphine for opioid use disorder

Update: 2018-03-20

Description

This episode features Dr. Andrew Saxon discussing treatments for opioid use disorder. Dr. Jennifer Mitty hosts.

Dr. Saxon is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington in Seattle, and he is Chair of the American Psychiatric Association's Council on Addiction Psychiatry.

References:
Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018; 391:30 9.

Tanum L, Solli KK, Latif ZE, et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry 2017; 74:11 97.

Contributor Disclosure: Grant/Research/Clinical Trial Support: Medicasafe [Medication dispensing]. Consultant/Advisory Boards: Neurocrine Biosciences [Tardive dyskinesia (Valbenazine)].

Comments

In Channel

Peanut oral immunotherapy in children and young adults

2018-05-3017:41

Digoxin levels and mortality in patients with atrial fibrillation

2018-05-2315:06

PERC criteria for ruling out pulmonary embolism

2018-05-1520:46

Under-recognition of fetal alcohol spectrum disorders

2018-05-0813:57

Time window for mechanical thrombectomy after acute ischemic stroke

2018-05-0115:32

Indications for surgery after a first episode of acute diverticulitis

2018-04-2411:26

Catheter ablation for atrial fibrillation with heart failure

2018-04-1715:55

Vaccination to prevent herpes zoster

2018-04-1013:53

Partially closed loop glucose monitoring in children and adolescents with type 1 diabetes

2018-04-0314:11

Third dose of MMR vaccine for prevention of mumps in an outbreak setting

2018-03-2715:54

Naltrexone versus buprenorphine for opioid use disorder

2018-03-2016:25

Monoclonal antibodies to prevent migraine; Oral fecal microbiota transplant for C. diff infection

2018-03-0629:32

Edoxaban vs low molecular weight heparin in cancer-related VTE; New treatment for cystic fibrosis

2018-02-2025:38

Management of suicide risk in children and adolescents; Increasing prevalence of syphilis in the US

2018-02-0638:24

Frequency for dosing of oral iron; Risk of late recurrence after endocrine therapy for breast cancer

2018-01-2331:04

Revised recommendations for endoscopy in dyspepsia; New hypertension criteria in ACC/AHA guidelines

2018-01-1037:54

PFO closure for prevention of recurrent stroke; Cost-effectiveness of triple therapy in RA

2017-12-1328:06

Investigational gene editing in human embryos to prevent disease; Tests for diagnosis of influenza

2017-11-2930:49

Prevention of HIV in high risk adolescents; ICDs for treatment of nonischemic cardiomyopathy

2017-11-1530:37

Zika virus prenatal infection and birth outcome; Evaluation for occult cancer in unprovoked VTE

2017-11-0123:02

00:00

Naltrexone versus buprenorphine for opioid use disorder

#box-pro-ellipsis-175949471399030{-webkit-line-clamp:2;}Naltrexone versus buprenorphine for opioid use disorder

Naltrexone versus buprenorphine for opioid use disorder

UpToDate

Naltrexone versus buprenorphine for opioid use disorder